Among them, ELAVL4 received the most attention in SCLC, because it was found to be expressed in 100% of SCLC cells and more than 50% of neuroblastoma cells, and treatment targeting ELAVL4 can reduce tumor progression in nude mouse models (Ohwada et al., 1999; Ehrlich et al., 2014). The gene discussed is ELAVL4; the disease is neoplasm.